Ira Pastor

Ira Pastor

Biography:

Ira S. Pastor is the Chief Executive Officer of Bioquark Inc. He has 30 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail; he served as VP, Business Development for the drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development.

Prior to that, he was employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance). He has an MBA from Temple University and a BS in Pharmacy, from Rutgers University.

Website(s):

Past Shows:

  • Modern Ghostbusting

    Christian D. Cadieux discussed his work authenticating and remediating unwanted paranormal activity (Related Photos).More »
  • Reanimation/ Monsterland

    BioQuark and Reanima CEO Ira S. Pastor discussed neuro-reanimation. Paranormal expert Ronny LeBlanc reported on strange occurrences in Massachusetts.More »
  • Reanimation Treatment/ Midweek Open Lines

    In the first half, CEO of Bioquark, Ira S. Pastor, discussed his latest work on the re-establishment of life after confirmed brain death using both biological and physical methods to stimulate nerves and awaken patients. Midweek Open Lines followed in the latter half, with a...More »

Last Night

Billy Meier UFO Case / Akashic Records & Angels
Billy Meier UFO Case / Akashic Records & Angels
Author and filmmaker Brit Elders discussed the case of the Swiss farmer Billy Meier, who claims to have met with Pleiadian aliens hundreds of times. Followed by Akashic Records master teacher Amy Robeson.

Coastzone

CoastZone banner
Sign up for our free CoastZone e-newsletter to receive exclusive daily articles.